Cagrilintide
Note: Peptides will arrive in a lyophilized (powder) form for maximum stability. Cagrilintide is a long-acting peptide analog of the naturally occurring hormone amylin, designed to support weight management and metabolic regulation through powerful appetite suppression and delayed gastric emptying. By mimicking amylin, Cagrilintide increases the feeling of fullness, helps regulate post-meal glucose levels, and promotes steady fat loss. It has shown promising results in clinical research both as a standalone therapy and when combined with GLP-1 agonists like semaglutide, where the effects on weight loss and blood sugar control are even more pronounced¹². Cagrilintide is an advanced investigational tool in obesity and metabolic research, offering a complementary mechanism to other gut hormone–based peptides.
Retatrutide
Note: Peptides will arrive in a lyophilized (powder) form for maximum stability. Retatrutide is a next-generation peptide designed to target three key hormone receptors in the body—GLP-1, GIP, and glucagon receptors—simultaneously. By combining the benefits of appetite suppression, increased calorie burning, and enhanced insulin sensitivity, Retatrutide has demonstrated exceptional potential in research focused on obesity, type 2 diabetes, and metabolic liver conditions. In clinical studies, participants experienced profound weight loss and improved metabolic health, making it one of the most promising research compounds under investigation for full-spectrum metabolic support¹²³.
Semaglutide
Note: Peptides will arrive in a lyophilized (powder) form for maximum stability. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has revolutionized the approach to metabolic health. It is best known for its powerful effects on weight loss, blood sugar regulation, and cardiovascular protection, but research has also revealed anti-inflammatory properties and emerging benefits for liver health, kidney function, and even neuroprotection. Originally developed to manage type 2 diabetes, semaglutide has become a leading candidate for broad-spectrum metabolic optimization, combining effectiveness with an excellent safety profile¹.
